🚀 VC round data is live in beta, check it out!
Genenta Science Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genenta Science and similar public comparables like NFL Biosciences, Argenica Therapeutics, Pharma Equity Group, Celyad Oncology and more.
Genenta Science Overview
About Genenta Science
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
Founded
2014
HQ
Employees
13
Website
Sectors
Financials (FY)
Market Cap
$17M
Genenta Science Financials
Genenta Science reported last fiscal year revenue of — and negative EBITDA of ($8M).
In the same fiscal year, Genenta Science generated ($8M) in EBITDA losses and had net loss of ($8M).
Revenue (LTM)
Genenta Science P&L
In the most recent fiscal year, Genenta Science reported revenue of — and EBITDA of ($8M).
Genenta Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($8M) | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genenta Science Stock Performance
Genenta Science has current market cap of $17M.
Market Cap Evolution
Genenta Science's stock price is $0.70.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $17M | -2.4% | XXX | XXX | XXX | $-0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenenta Science Valuation Multiples
Genenta Science trades at 1.0x EV/EBITDA.
EV / Revenue (LTM)
Genenta Science Financial Valuation Multiples
As of April 18, 2026, Genenta Science has market cap of $17M.
Equity research analysts estimate Genenta Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genenta Science has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17M | XXX | $17M | XXX | XXX | XXX |
| EV (current) | ($8M) | XXX | ($8M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 1.0x | XXX | XXX | XXX |
| P/E | — | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genenta Science Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genenta Science Margins & Growth Rates
Genenta Science's revenue in the last fiscal year grew by —.
Genenta Science's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Genenta Science Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (32%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genenta Science Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Genenta Science | XXX | XXX | XXX | XXX | XXX | XXX |
| NFL Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Argenica Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharma Equity Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Celyad Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| NextCell Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genenta Science M&A Activity
Genenta Science acquired XXX companies to date.
Last acquisition by Genenta Science was on XXXXXXXX, XXXXX. Genenta Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genenta Science
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenenta Science Investment Activity
Genenta Science invested in XXX companies to date.
Genenta Science made its latest investment on XXXXXXXX, XXXXX. Genenta Science invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genenta Science
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genenta Science
| When was Genenta Science founded? | Genenta Science was founded in 2014. |
| Where is Genenta Science headquartered? | Genenta Science is headquartered in Italy. |
| How many employees does Genenta Science have? | As of today, Genenta Science has over 13 employees. |
| Who is the CEO of Genenta Science? | Genenta Science's CEO is Pierluigi Paracchi. |
| Is Genenta Science publicly listed? | Yes, Genenta Science is a public company listed on Nasdaq. |
| What is the stock symbol of Genenta Science? | Genenta Science trades under GNTA ticker. |
| When did Genenta Science go public? | Genenta Science went public in 2021. |
| Who are competitors of Genenta Science? | Genenta Science main competitors are NFL Biosciences, Argenica Therapeutics, Pharma Equity Group, Celyad Oncology. |
| What is the current market cap of Genenta Science? | Genenta Science's current market cap is $17M. |
| Is Genenta Science profitable? | No, Genenta Science is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.